CLDN18 and gastric cancer: Satricabtagene autoleucel, a CAR-T therapy targeting CLDN18.2, demonstrates high efficacy with a 91.8% DCR and 8.8-month median OS in advanced gastrointestinal cancers, offering a promising new option for refractory GC when combined with PD-1 inhibitors (99).